Roche fields first approval for Rozlytrek in the run-up to a showdown with Bayer, Pfizer
While it’s waiting to hear back from FDA regulators, Roche is beginning the victory lap for entrectinib in Japan.
Roche is giving Bayer a run for their money with this tumor-agnostic drug, which targets NTRK gene fusions. Now dubbed Rozlytrek, it’s sanctioned to treat adult and pediatric patients in Japan with neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.